Xmetix
Xmetix is an Israeli private defensetech startup that developed the TAK710, the first automatic tourniquet for mass casualty events, with interest from international governments including Australia.
Visit WebsiteCompany Overview
Xmetix develops advanced medical devices for tactical and mass casualty environments. The company's flagship product, the TAK710, is the first automatic tourniquet designed for rapid deployment in battlefield and mass casualty scenarios. CEO Edan Razinovsky developed the product in response to the mass casualty events of October 2023.
Featured at the Defense Tech Expo 2026 in Tel Aviv, Xmetix reported interest from international governments, including Australia, for use in both military and public safety contexts.
Dual-use relevance is very high: automatic tourniquets serve both military tactical medicine and civilian emergency response, law enforcement, and public safety applications.
Dual-Use Assessment
Automatic tourniquet technology serves military combat medicine and civilian mass casualty response, law enforcement, and emergency medical services.
Key Technologies
- Automatic tourniquet deployment mechanism
- Rapid hemorrhage control systems
- Tactical medical device miniaturization
- One-hand operation combat medical devices
- Mass casualty triage support equipment
Use Cases & Applications
- Battlefield hemorrhage control for soldiers
- Mass casualty event rapid response
- Law enforcement tactical medical kits
- Emergency medical services equipment
- Public safety preparedness for active threat scenarios
Strategic Value to U.S.-Israel Alliance
Automatic tourniquets can save lives on the battlefield and in mass casualty events, directly supporting allied force survivability and civilian resilience.
Interested in this startup?
Learn more about our investment approach or get in touch to discuss opportunities in dual-use technology.